These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26728875)

  • 1. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
    D'Amore C; Da Cas R; Rossi M; Traversa G
    BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
    Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
    BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.
    Gaipov A; Issanov A; Mursalova Z; Tulegenova N; Kakim Z; Baizakov M; Tuganbekova S; Aljofan M
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00594. PubMed ID: 32524766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
    Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
    BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
    Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
    BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic substitution of antidiabetic drugs in the elderly does not affect adherence.
    Trotta F; Da Cas R; Maggini M; Rossi M; Traversa G
    Ann Ist Super Sanita; 2014; 50(4):333-40. PubMed ID: 25522073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
    Okano M; Sato M; Kaneko E; Kageyama S
    Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.
    Jelkmann W
    Expert Opin Biol Ther; 2012 May; 12(5):581-92. PubMed ID: 22471247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of switching between therapeutic proteins.
    Ebbers HC; Muenzberg M; Schellekens H
    Expert Opin Biol Ther; 2012 Nov; 12(11):1473-85. PubMed ID: 22849511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.
    Perrone V; Saragoni S; Buda S; Broccoli A; Degli Esposti L
    Biologics; 2016; 10():157-165. PubMed ID: 27942203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W
    Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.
    Mielke J; Woehling H; Jones B
    Pharm Stat; 2018 May; 17(3):231-247. PubMed ID: 29424120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.